Cardiac glycosides are drugs that make the heart squeeze harder and slow electrical conduction through the AV node. In Intro to Pharmacology, they come up as heart failure and antiarrhythmic medications, especially digoxin.
Cardiac glycosides are a class of heart medications in Intro to Pharmacology that increase the force of cardiac contraction and slow conduction through the atrioventricular, or AV, node. That combination makes them useful when the heart is pumping weakly, especially in heart failure, and when a slower, more controlled ventricular response is needed in certain arrhythmias.
The classic example is digoxin. When you see this term in a pharmacology course, think of a drug with two big effects: positive inotropy, meaning stronger contractions, and slowed AV node conduction, which can help calm a rapid rhythm. Those effects make it different from drugs that only lower blood pressure or only change heart rate.
The mechanism is tied to the Na+/K+ ATPase pump. Cardiac glycosides inhibit that pump, which raises intracellular sodium. That sodium change reduces the cell's ability to move calcium out, so more calcium stays available inside the cardiac cell. More intracellular calcium means the muscle fiber can contract more forcefully. This is the core mechanism you need to connect to the clinical effect.
This drug class is narrow in its margin of safety. Digoxin is the name you will see most often, and it requires careful monitoring because a small increase in dose can push it toward toxicity. That is why the term is usually taught alongside therapeutic index, lab monitoring, and patient safety. In real pharmacology problems, the question is not just what the drug does, but whether the patient is at risk of taking too much.
Side effects are another big clue. Nausea, vomiting, and visual changes can show up when a patient is developing toxicity. Low potassium, or hypokalemia, raises the risk because it makes digoxin's effects more dangerous. So if a case mentions a patient on a cardiac glycoside with vomiting, yellow-tinted vision, or low potassium, that is a strong red flag to think about toxicity rather than a routine side effect.
A simple way to remember the class is that cardiac glycosides help a weak heart pump more effectively, but they do not do it gently enough to ignore monitoring. In pharmacology, that balance between benefit and risk is the whole story.
Cardiac glycosides matter because they tie together three core Intro to Pharmacology ideas at once: mechanism of action, therapeutic use, and toxicity. You are not just memorizing a drug name. You are learning how a change at the membrane pump level can alter calcium handling, contractility, and rhythm.
This term also helps you sort out heart failure medications from antiarrhythmics. Some drugs mainly reduce workload, some slow electrical activity, and some improve pump strength. Cardiac glycosides sit at the intersection of those categories, which makes them a common comparison point in class discussions and case questions.
They are also a good example of why pharmacology is never just about the desired effect. A narrow therapeutic index, electrolyte status, and symptoms like nausea or visual disturbance all matter when you interpret a patient scenario. If a case gives you low potassium and digoxin, you should immediately think about increased toxicity risk.
In other words, the term trains you to connect physiology to medication safety. That is exactly the kind of thinking pharmacology asks for when you move from a drug list to a real patient story.
Keep studying Intro to Pharmacology Unit 7
Visual cheatsheet
view galleryDigoxin
Digoxin is the best-known cardiac glycoside, so most class questions use it as the example drug. If a prompt asks about dosing, toxicity, or monitoring, digoxin is usually the drug you are expected to recognize. The class mechanism explains why digoxin strengthens contraction and why it can become dangerous when levels rise too high.
Heart Failure
Cardiac glycosides are often discussed in heart failure because they can improve cardiac output when the heart is not pumping effectively. In that setting, the stronger contraction matters more than a simple heart-rate change. When you see a patient with fatigue, fluid backup, and reduced pumping ability, the term helps you connect the medication to the underlying problem.
Arrhythmia
The AV node effect makes cardiac glycosides relevant to certain arrhythmias, especially when the goal is to slow conduction and control rate. That is a different use than heart failure, so the same drug class can show up in two distinct clinical roles. This is useful when you need to compare a rhythm problem with a pumping problem.
Contraindicated Medications
Cardiac glycosides often appear in safety questions alongside drug interactions and contraindications. The big idea is that a medication with a narrow therapeutic index can become risky when paired with the wrong agent or when electrolytes are off. If a question asks what makes a patient unsafe for digoxin therapy, this connection helps you think beyond the drug itself.
A quiz question might ask you to match a drug with its mechanism, and cardiac glycosides should cue you to think about Na+/K+ ATPase inhibition, increased intracellular calcium, and stronger contraction. In a case study, you may need to spot digoxin toxicity from nausea, vomiting, blurred or odd-colored vision, or low potassium. You may also be asked why the drug slows the heart, which points to AV node conduction.
If the question gives a patient with heart failure and an arrhythmia history, the task is usually to decide whether a cardiac glycoside fits the scenario or whether the symptoms point to toxicity. In short-answer or discussion work, use the term to connect mechanism, therapeutic use, and adverse effects in one chain. That is the move pharmacology instructors look for.
Cardiac glycosides and beta-blockers can both slow heart rate, so they get mixed up. The difference is that cardiac glycosides also increase contractility through calcium handling, while beta-blockers mainly reduce sympathetic stimulation and heart workload. If the question centers on stronger pumping plus AV node slowing, think cardiac glycosides. If it centers on blocking adrenergic effects, think beta-blockers.
Cardiac glycosides are heart drugs that make contractions stronger and slow AV node conduction.
Digoxin is the classic example, so the class is often taught through that one medication.
Their mechanism starts with Na+/K+ ATPase inhibition and ends with increased intracellular calcium.
They can help in heart failure and some arrhythmias, but they have a narrow therapeutic index.
Nausea, vomiting, visual changes, and low potassium are warning signs that point toward toxicity.
Cardiac glycosides are a class of heart medications that increase the strength of cardiac contraction and slow AV node conduction. In Intro to Pharmacology, they are usually discussed as drugs for heart failure and some arrhythmias, with digoxin as the main example.
They inhibit the Na+/K+ ATPase pump in cardiac cells. That raises intracellular sodium, which leads to more intracellular calcium and a stronger contraction. The AV node slowing effect is why they can also help control certain rhythms.
Common warning signs include nausea, vomiting, and visual disturbances. Toxicity is more likely when potassium is low, because hypokalemia makes digoxin's effects more dangerous. In case questions, those clues usually point to a safety issue rather than a routine side effect.
No. They can both lower heart rate, but they do it in different ways. Cardiac glycosides also strengthen contraction, while beta-blockers mainly block sympathetic stimulation. That difference matters when you are matching a drug to a heart failure or arrhythmia scenario.